Citigroup
ACRS icon

Citigroup’s Aclaris Therapeutics ACRS Stock Holding History

Citigroup’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.3K Sell
7,826
-33,804
-81% -$114K ﹤0.01% 4711
2025
Q4 		$125K Buy
41,630
+39,695
+2,051% +$100K ﹤0.01% 4219
2025
Q3 		$3.68K Sell
1,935
-29,270
-94% -$51K ﹤0.01% 5322
2025
Q2 		$44.3K Buy
31,205
+25,056
+407% +$33.9K ﹤0.01% 4826
2025
Q1 		$9.41K Sell
6,149
-53,823
-90% -$115K ﹤0.01% 5210
2024
Q4 		$149K Buy
59,972
+57,885
+2,774% +$144K ﹤0.01% 4618
2024
Q3 		$2.4K Sell
2,087
-11,384
-85% -$14K ﹤0.01% 5398
2024
Q2 		$14.8K Buy
13,471
+1,136
+9% +$1.33K ﹤0.01% 5074
2024
Q1 		$15.3K Sell
12,335
-495,173
-98% -$590K ﹤0.01% 5105
2023
Q4 		$533K Buy
507,508
+495,644
+4,178% +$1.51M ﹤0.01% 3364
2023
Q3 		$81.3K Sell
11,864
-18,213
-61% -$156K ﹤0.01% 3993
2023
Q2 		$312K Sell
30,077
-46,465
-61% -$420K ﹤0.01% 3660
2023
Q1 		$619K Buy
76,542
+58,256
+319% +$739K ﹤0.01% 2960
2022
Q4 		$288K Buy
18,286
+10,003
+121% +$161K ﹤0.01% 3534
2022
Q3 		$130K Sell
8,283
-5,156
-38% -$81.2K ﹤0.01% 3974
2022
Q2 		$187K Buy
13,439
+5,047
+60% +$70.7K ﹤0.01% 3884
2022
Q1 		$145K Sell
8,392
-9,199
-52% -$125K ﹤0.01% 4244
2021
Q4 		$256K Sell
17,591
-6,752
-28% -$102K ﹤0.01% 4208
2021
Q3 		$438K Buy
24,343
+15,330
+170% +$246K ﹤0.01% 3696
2021
Q2 		$158K Buy
9,013
+2,840
+46% +$64.5K ﹤0.01% 4334
2021
Q1 		$156K Sell
6,173
-36,302
-85% -$710K ﹤0.01% 4141
2020
Q4 		$275K Buy
+42,475
New +$179K ﹤0.01% 4742
2020
Q2 		– Sell
-9,838
Closed -$10K – 7512
2020
Q1 		$10K Buy
9,838
+3,652
+59% +$4.97K ﹤0.01% 7032
2019
Q4 		$12K Buy
6,186
+4,073
+193% +$6.75K ﹤0.01% 7130
2019
Q3 		$2K Sell
2,113
-14,741
-87% -$20.9K ﹤0.01% 7516
2019
Q2 		$37K Buy
16,854
+3,601
+27% +$19.6K ﹤0.01% 6716
2019
Q1 		$79K Buy
13,253
+9,260
+232% +$61.4K ﹤0.01% 5966
2018
Q4 		$30K Buy
3,993
+3,872
+3,200% +$39.9K ﹤0.01% 6618
2018
Q3 		$1K Buy
121
+60
+98% +$1.03K ﹤0.01% 7644
2018
Q2 		$1K Sell
61
-58
-49% -$1.07K ﹤0.01% 7510
2018
Q1 		$2K Sell
119
-81
-41% -$1.72K ﹤0.01% 7345
2017
Q4 		$5K Buy
200
+126
+170% +$3.07K ﹤0.01% 7215
2017
Q3 		$2K Sell
74
-4,239
-98% -$114K ﹤0.01% 7006
2017
Q2 		$117K Buy
4,313
+2,726
+172% +$74.1K ﹤0.01% 5229
2017
Q1 		$47K Sell
1,587
-9,884
-86% -$285K ﹤0.01% 5739
2016
Q4 		$311K Buy
11,471
+10,617
+1,243% +$271K ﹤0.01% 4891
2016
Q3 		$22K Sell
854
-127
-13% -$2.69K ﹤0.01% 6146
2016
Q2 		$18K Sell
981
-7,509
-88% -$149K ﹤0.01% 6216
2016
Q1 		$161K Buy
8,490
+6,754
+389% +$129K ﹤0.01% 5286
2015
Q4 		$47K Buy
+1,736
New +$33.8K ﹤0.01% 5980

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citigroup's ACRS Position: Q1 2026 in Review

Citigroup reduced its Aclaris Therapeutics (ACRS) stake by 81% in Q1 2026, selling an estimated $114K and leaving 7,826 shares worth $29.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4711.

Citigroup first reported a position in ACRS in Q4 2015 and has held it in 40 quarters since. The position peaked at $619K in Q1 2023. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Citigroup held 7,826 shares of Aclaris Therapeutics worth $29.3K as of Q1 2026.
  • Citigroup sold 33,804 Aclaris Therapeutics shares in Q1 2026, an estimated $114K.
  • Aclaris Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4711 holding.
  • Citigroup first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 40 quarters since.
  • Citigroup's Aclaris Therapeutics position peaked at $619K in Q1 2023.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.